New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
05:41 EDTBIIBBiogen, Eisai enter collaboration develop, commercialize Alzheimer’s treatments
Eisai and Biogen Idec announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease, or AD, E2609 and BAN2401. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idec’s candidates for AD, the anti-amyloid beta antibody BIIB037 and an anti-tau monoclonal antibody. The collaboration initially will be centered on the co-development and co-commercialization of Eisai’s two candidates: E2609, a beta-site amyloid precursor protein cleaving enzyme, or BACE, inhibitor, and BAN2401, an anti-amyloid beta antibody. These candidates have the potential to reduce amyloid beta plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression. Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments. The agreement also includes options for Eisai to receive an additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.
News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
09:07 EDTBIIBBiogen price target raised to $474 from $432 at BMO Capital
Subscribe for More Information
06:24 EDTBIIBBiogen price target raised to $387 from $343 at Citigroup
Citigroup raised its price target for Biogen shares to $387 citing the company's earnings and revenue growth following its better than expected Q2 results. Citi keeps a Buy rating on the stock.
July 23, 2014
11:43 EDTBIIBBiogen announces PLEGRIDY EC approval
Subscribe for More Information
10:25 EDTBIIBBiogen price target raised to $420 from $370 at Piper Jaffray
Subscribe for More Information
09:50 EDTBIIBBiogen says strategic bias still tuck-in acquisitions
Subscribe for More Information
09:37 EDTBIIBBiogen says 'clearly' has considered tax inversion
Subscribe for More Information
09:25 EDTBIIBBiogen sees Japan as an attractive growth opportunity for company
Says remains committed to SG&A leverage in 2014. Says guidance assumes Tecfidera EU uptake similar to U.S.
09:17 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTBIIBBiogen says received letter from EU saying PLEGRIDY has been approved
Subscribe for More Information
08:56 EDTBIIBBiogen still sees FY CapEx approximately $300M
Believes TECFIDERA is on track to become the leading MS product in the U.S. Says outside the U.S., demand for TECFIDERA has been broad; launch trajectories similar to experience in U.S. Continues to be in discussions with AIFA to resolve its dispute on Tysabri for February 2009-January 2013. Says FY guidance "meaningfully increased" due primarily to the  growth  of  TECFIDERA in the U.S. and the EU., the strength of our other MS therapies and clarity on the AIFA pricing matter. Comments from slides that will be presented on the Q2 earnings conference call.
06:50 EDTBIIBBiogen raises FY14 EPS to $12.90-$13.10 from $11.35-$11.45, consensus $11.53
Subscribe for More Information
06:48 EDTBIIBBiogen reports Q2 Tecfidera revenue $700M; Reports Q2 Avonex revenue $774M
Subscribe for More Information
06:47 EDTBIIBBiogen reports Q2 adjusted EPS $3.49, consensus $2.83
Reports Q2 revenue $2.42B, consensus $2.16B; Non-GAAP diluted EPS was benefited by approximately 15c, following the approval from an agreement with the Italian National Medicines Agency relating to Tysabri sales in Italy.
July 22, 2014
14:30 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
July 21, 2014
07:37 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use